FDA Approves Foundayo as Fifth NPV-Program Drug

To date, the FDA has awarded 18 vouchers and issued six program decisions.

Benefits attributed to the program include enhanced communication, rolling review features, and a shortened review timeline that aims to preserve safety and scientific integrity.

The agency has targeted a two-month decision window under the program, with flexibility for extended reviews determined by scientific review needs.

• The FDA issued approval for Foundayo, the active pharmaceutical ingredient orforglipron, marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.
• The decision occurred 50 days after filing and 294 days prior to the application’s PDUFA date set for January 20, 2027, distinguishing it as the fastest NMEs approval since 2002 and the first NME approved through this voucher-driven pathway.
• The CNPV program, initiated in 2025, is designed to accelerate approvals for applications aligned with critical national health priorities.

It is designed to be taken once daily.

Depending on response and tolerability, dose levels may continue to escalate to 9 mg, 14.5 mg, and 17.2 mg, with each step contingent on clinical response and tolerability assessed over at least 30-day intervals.

• Foundayo is a glucagon-like peptide-1 (GLP-1) receptor agonist formulated as an oral tablet.
• The initial treatment regimen begins at 0.8 mg daily, with planned titration to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days.
• The approved indication specifies use in adults with obesity or overweight who have at least one weight-related comorbidity, in combination with a reduced-calorie diet and increased physical activity, with the goal of reducing excess body weight and maintaining weight loss long term.

• The decision rested on evidence from two randomized, double-blind, placebo-controlled trials conducted in adults who were obese or overweight and had one or more weight-related comorbid conditions.
• Across 72 weeks of treatment, individuals receiving Foundayo in addition to lifestyle interventions experienced a statistically significant, clinically meaningful greater reduction in body weight compared with those receiving placebo.
• The sponsor-supported trials contributed to the benefit-risk assessment that supported the approval under the CNPV framework, reflecting a streamlined yet rigorous evaluation process in this program.

• The drug's safety profile includes a spectrum of common adverse events: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, abdominal distention, headache, abdominal bloating, fatigue, belching, gastroesophageal reflux, gas (flatulence), and hair loss.
• Notable warnings and precautions accompany the labeling, including risks for pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia, hypersensitivity reactions, diabetic retinopathy in patients with type 2 diabetes mellitus, acute gallbladder disease, and potential pulmonary aspiration during general anesthesia or deep sedation.
• Foundayo carries a boxed warning for thyroid C-cell tumors and should not be used by patients with personal or family histories of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
• A plus for clinical practice notes: the labeling specifies that Foundayo should not be used concurrently with another GLP-1 receptor agonist.
• The FDA’s communications also emphasize continuous safety monitoring and risk mitigation as part of the post-approval framework.

Commissioner statements highlighted eliminating idle time and maintaining robust agency-industry communications to shorten the review timeline.

• FDA leadership framed the approval as an exemplar of how the CNPV pilot can expedite access to meaningful therapeutics while preserving rigorous scientific standards.
• Acting CDER leadership underscored that CDER delivered a thorough product review and benefit-risk assessment, commenting that months were shaved from the traditional filing-to-decision interval without compromising safety or quality of review.
• The regulatory process under the CNPV included heightened collaboration, rolling reviews, and clarified expectations for sponsor responsibilities and pre-submission requirements, with opportunities for public engagement and comment on program parameters.

The implications of this meeting for ongoing program refinement are not further detailed in the source.

• The source text specifies the existence of two pivotal randomized trials supporting efficacy but does not disclose granular efficacy metrics, population characteristics beyond a broad obesity/overweight category, or detailed subgroup analyses.
• While safety signals are enumerated, precise incidence rates, exposure-response data, and comparative tolerability relative to placebo or other GLP-1 agents are not provided in the source.
• The text mentions a planned public meeting scheduled for June 4 (rescheduled from June 12) to solicit feedback on various elements of the CNPV program, with written comments due by June 29, 2026.
• There is no explicit information on long-term outcomes beyond the 72-week trial horizon nor postmarketing commitments or real-world safety data in this digest.

Clinicians should note the titration schedule and the spectrum of potential adverse effects and warnings, as well as the contraindications related to medullary thyroid pathology and MEN2.

• Foundayo represents a newly available oral GLP-1 receptor pathway agent for weight management in adults with obesity or overweight and comorbidity in the context of lifestyle modification.
• Providers should remain alert to the drug’s specific safety concerns, including potential pancreatitis, renal injury risk due to dehydration, hypoglycemia, retinal considerations in diabetes, and gallbladder disease, among others.